Is pregnancy an absolute contraindication for a woman with pulmonary arterial hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pregnancy in Women with Pulmonary Arterial Hypertension

Yes, pregnancy is considered an absolute contraindication in women with pulmonary arterial hypertension (PAH), particularly those with severe disease or Eisenmenger physiology, due to unacceptably high maternal mortality risk. 1

Strength of Contraindication

The ACC/AHA guidelines explicitly state that pregnancy in women with CHD-PAH, especially those with Eisenmenger physiology, is not recommended and should be absolutely avoided in view of the high risk of maternal mortality (Class III recommendation, Level of Evidence B). 1 Women with severe CHD-PAH and their partners should be counseled about the absolute avoidance of pregnancy 1.

Mortality Risk

The mortality risk varies by severity and etiology:

  • Historical data showed maternal mortality rates of 30-50% in PAH patients, with rates of 36% in Eisenmenger syndrome, 30% in idiopathic PAH (IPAH), and 56% in associated pulmonary hypertension 1.

  • More recent data indicates improved outcomes with maternal mortality of approximately 12% when PAH is well controlled 1, though a 2025 meta-analysis reported 7.6% overall maternal mortality 2.

  • Severe PAH remains associated with significantly higher mortality (OR 5.57) compared to mild/moderate disease 2.

  • Most deaths (93%) occur in the postpartum period, with particular risk in the first several days after delivery 1.

Physiologic Basis for Contraindication

Pregnancy imposes extreme hemodynamic stress that PAH patients cannot tolerate 1:

  • 30-50% increase in blood volume and cardiac output 1
  • 10-20 beat/min increase in heart rate 1
  • Increased stroke volume with decreased systemic vascular resistance 1
  • Peak hemodynamic changes at 20-24 weeks gestation 1
  • Dramatic volume shifts immediately postpartum from vena cava decompression and return of uterine blood to systemic circulation 1
  • Hormonal changes during and after pregnancy may be pathophysiologically detrimental, potentially causing permanent worsening of pulmonary hypertension even after successful delivery 1

Fetal Risks

Beyond maternal mortality, pregnancy in PAH carries substantial fetal risks 1:

  • Increased incidence of small-for-gestational-age infants 1
  • Increased congenital anomalies 1
  • Higher rates of abortion (OR 3.64), prematurity (OR 2.52), and small gestational age (OR 3.96) in severe PAH 2

Management When Pregnancy Occurs

If pregnancy does occur despite contraindication 1:

First trimester:

  • Earliest possible pregnancy termination should be recommended after individualized counseling from cardiovascular and obstetric caregivers with CHD-PAH expertise 1.
  • First trimester termination is the safer option compared to later termination 1.

Second and third trimesters:

  • Termination in the last 2 trimesters poses high maternal risk but may be reasonable after balancing risks of termination against continuation (Class IIb) 1.

If pregnancy continues:

  • Care must occur at a pulmonary hypertension center using a multidisciplinary approach including pulmonary hypertension specialists, high-risk obstetrics, and cardiovascular anesthesiology 1.
  • Early hospitalization for monitoring once fetus is viable 1.
  • Supportive therapy with cautious fluid management, supplemental oxygen, diuretics, and dobutamine as needed 1.
  • Pulmonary artery catheter for close hemodynamic monitoring may be helpful 1.

Contraception Recommendations

Given the absolute contraindication to pregnancy, effective contraception is mandatory 1:

  • Single-barrier contraception alone is not recommended due to high failure rates (Class III) 1.
  • Estrogen-containing contraceptives should be avoided due to increased thromboembolism risk (Class III) 1.
  • Progesterone-only preparations (medroxyprogesterone acetate, etonogestrel) are safer options 1.
  • Dual mechanical barrier contraceptive techniques are recommended for patients taking bosentan, ambrisentan, macitentan, or riociguat (Category X medications) 1.
  • Surgical sterilization carries operative risk but is safer than pregnancy; minimally invasive techniques should be discussed with experienced obstetricians and cardiac anesthesiologists 1.

Nuances and Evolving Evidence

While the absolute contraindication remains in place, recent data suggests outcomes may be improving with modern PAH therapies and multidisciplinary care 1, 2. However, severe PAH continues to carry unacceptably high mortality risk 2. The European Society of Cardiology guidelines note that pregnancy remains contraindicated (mWHO class IV) but acknowledge that a recent report showed 12% maternal mortality with 62% successful pregnancies, particularly in well-controlled PAH and long-term calcium channel blocker responders 1. These data require confirmation by larger series before reconsidering the general recommendation 1.

The current consensus remains that pregnancy should be absolutely avoided in PAH, with the strongest contraindication in severe disease and Eisenmenger physiology. 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

In which heart disease is pregnancy an absolute contraindication?
Do pre-capillary pulmonary hypertension and post-capillary pulmonary hypertension carry the same risk in pregnancy?
Which cardiac condition is a modified World Health Organization (WHO) Risk Class IV lesion for which pregnancy is extremely dangerous and not recommended: Repaired Ventricular Septal Defect (VSD), Pulmonary Artery Hypertension (PAH), Supraventricular Arrhythmias, or Hypertrophic Cardiomyopathy?
How to manage moderate pulmonary hypertension (PH) diagnosed on 2D echocardiogram (2D echo) during pregnancy?
What is the best method of termination for a pregnancy at 16 weeks in a patient with congenital heart disease, atrial septal defect (ASD) with Eisenmengerization, and hypoxemia, who is otherwise hemodynamically stable?
Should I take a quarter tablet of Senokot S (senna) daily together with polyethylene glycol (PEG) for three months to ease a hard second bowel movement despite having two stools per day?
In a healthy adult who completed the hepatitis B vaccination series ten years ago, what are the recommendations after inadvertently receiving an extra hepatitis B vaccine dose?
What are the clinical features of mitral stenosis, ordered from most common to least common?
What is the recommended treatment for Pneumocystis jirovecii pneumonia?
In a 41‑year‑old female with a normal‑sized spleen (9.6 cm) and increased splenic parenchymal echogenicity on ultrasound, what is the clinical significance and recommended work‑up?
What is the recommended evaluation and management for an intrathoracic lipoma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question